Skip to content

Preventing Loss of Independence Through Exercise (PLIÉ) - Pilot

Maintaining Independence in Alzheimer's Disease

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01371214
Acronym
PLIÉ-pilot
Enrollment
12
Registered
2011-06-10
Start date
2011-06-30
Completion date
2012-09-30
Last updated
2015-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia

Keywords

exercise, exercise movement techniques, activities of daily living

Brief summary

The primary goal of this study is to perform a 36-week pilot study with a cross-over design to study the safety and efficacy of a novel integrative exercise program called PLIÉ (Preventing Loss of Independence through Exercise). PLIÉ integrates elements of Eastern and Western exercise traditions and is specifically designed to target the muscles and movements needed to help individuals with mild-to-moderate dementia maintain physical function and independence.

Interventions

BEHAVIORALPLIÉ (Preventing Loss of Independence through Exercise)

Integrative exercise program that incorporates elements of Eastern and Western exercise traditions to target the muscles and movements needed to help individuals with mild to moderate dementia maintain functional status and independence.

Sponsors

University of California, San Francisco
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

- Primary Participant: * Current participant in the Irene Swindells Center for Adult Day Services in San Francisco, CA * Recommended by Swindells staff * mild-to-moderate dementia * caregiver consent Inclusion Criteria - Caregiver: * Provide care to primary participant in the Irene Swindells Center for Adult Day Services in San Francisco, CA * can provide information about the primary participant's physical functioning, behaviors, falls, quality of life and own level of stress.

Exclusion criteria

- Primary Participant: * major current psychiatric illness (e.g., schizophrenia, bipolar disorder) * life expectancy \< 1 year (e.g., metastatic cancer) * inability to assent to study procedures

Design outcomes

Primary

MeasureTime frameDescription
Change in dementia-related behaviors (participant)Baseline, 18 weeks, 36 weeksParticipant's dementia-related behaviors will be assessed with the Neuropsychiatric Inventory (NPI), which is a 144-point informant-based questionnaire that assesses 12 behavioral domains common in dementia including frequency, severity and impact on caregiver distress (Cummings 1997).
Compliance (participant)Baseline, 18 weeks, 36 weeksParticipant compliance will be determined based on % of exercise classes attended from baseline to 18 weeks and from 18-36 weeks.
Adverse events (participant)Baseline, 18 weeks, 36 weeksNumber of adverse events from baseline to 18 weeks and from 18 weeks to 36 weeks will be monitored through biweekly telephone calls with caregivers.
Change in physical function (participant)Baseline, 18 weeks, 36 weeksParticipant's physical function will be assessed with the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) scale (Galasko 1997). The ADCS-ADL is a 78-point scale that assesses functional ability in 23 daily activities based on informant report. It is the standard measure for assessment of functional status in AD treatment trials.
Change in quality of life (participant)Baseline, 18 weeks, 36 weeksQuality of life will be assessed with the Quality of Life Scale in Alzheimer's Disease (QOL-AD), which is a brief, 13-item measure that obtains input from both the individual and the caregiver (Logsdon 1999). Scores may range from 13-52 points.
Change in functional health and well-being (participant)Baseline, 18 weeks, 36 weeksFunctional health and well-being will be assessed with the SF-36v2, which assesses function in eight domains and provides physical and mental component summary scores that may range from 0 to 70 (Stewart 1989). The SF-36v2 is typically administered directly to participants. However, we also will ask caregivers to answer questions on behalf of participants and will compare their answers to assess congruence. Data collected will help to determine if this measure is suitable for a larger trial.
Change in number of falls (participant)Baseline, 18 weeks, 36 weeksParticipant's falls will be assessed based on caregiver report.
Change in fall-related self-efficacy (participant)Baseline, 18 weeks, 36 weeksFall-related self-efficacy will be assessed with the Falls Efficacy Scale (FES), which is a 10-item scale that has been validated in individuals with cognitive impairment (Hauer 2010).
Change in physical performance (participant)Baseline, 18 weeks, 36 weeksPhysical performance will be assessed with the Short Physical Performance Battery (SPPB), which was developed by the National Institute on Aging to provide an objective tool for evaluating lower extremity functioning in older adults. The test includes repeated chair stands, tandem balance testing and 8' walking speed (Guralnik 1994).
Change in cognitive function (participant)Baseline, 18 weeks, 36 weeksCognitive function will be assessed with the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) (Rosen 1984), which is the most commonly used primary outcome measure in AD treatment trials. It is an 80-point scale that includes direct assessment of learning (word list), naming (objects), following commands, constructional Praxis (figure copying), ideational Praxis (mailing a letter), orientation (person, time, place), recognition memory and remembering test instructions.

Secondary

MeasureTime frameDescription
Change in burden (caregiver)Baseline, 18 weeks, 36 weeksCaregiver burden will be assessed with the Caregiver Burden Inventory (CBI), which is a 96-point scale that includes 24 items and 5 domains (Novak 1989).
Change in functional health and well-being (caregiver)Baseline, 18 weeks, 36 weeksCaregivers will be asked about the functional health and well-being of themselves as well as participants using the SF-36v2, which assesses function in eight domains and provides physical and mental component summary scores that may range from 0 to 70 (Stewart 1989).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026